Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.
|ジャーナル||Nippon rinsho. Japanese journal of clinical medicine|
|出版ステータス||出版済み - 4月 2005|
!!!All Science Journal Classification (ASJC) codes